Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsTheclinical comparative study met its primary endpoint and showed similar efficacyand comparable safety profile in patients with moderate to severe plaque psoriasis GUANGZHOU,China, November 29, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177:SH),a commercial-stage biopharmaceutical company d...
GUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of biosesimilarsand innovative assets, announced that the National Health Surveillance Agency(“ANVISA”) published the approval of the certification of good m...
TOFIDENCE is Bio-Thera’s first productapproved by USFDA. TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United States TOFIDENCE is the first biosesimilar toActemra approved by USFDA GUANGZHOU, C...
